CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
CareDx, Inc. has highlighted the significance of equity in transplantation at the 2021 American Transplant Congress. Dr. Hannah Valantine's keynote lecture emphasized using genomics to address health disparities in organ transplantation. Valantine presented the AlloMap IMAGE trial as crucial for understanding minority population insights, with dd-cfDNA identified as a key tool for personalizing care. CareDx aims to ensure all end-stage disease patients have equitable access to transplant resources, showcasing its commitment to diversity in transplant medicine.
- Dr. Hannah Valantine's keynote at the ATC showcased CareDx's commitment to equity in transplantation.
- The AlloMap IMAGE trial is recognized for addressing insights into minority populations.
- CareDx is building a reputation for leadership in transplant medicine through significant presentations.
- None.
Valantine’s ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, congratulates Hannah Valantine, MD on her State of the Art Lecture at the 2021 American Transplant Congress (ATC) about the importance of equity in transplantation and genomic solutions to improve inclusivity.
On Tuesday, June 8, Hannah Valantine gave a keynote talk titled “Inclusive Excellence in Biomedical Research: Applying Genomics To Unravel Health Disparities In Organ Transplantation.” In addition to Valantine’s work in transplant science and innovation throughout the years, she has deep expertise in leading diversity efforts. Most recently, she served for six years as the inaugural National Institute of Health (NIH) Chief Officer for Scientific Workforce Diversity. In the ATC keynote talk, Valantine highlighted the AlloMap IMAGE trial as an example of the critical large-scale studies that are required to capture insights for minority populations. She also highlighted dd-cfDNA as a key tool in identifying racial disparities and personalizing care.
CareDx believes strongly in equity for transplant patients, ensuring all end stage disease patients have access to transplant waiting lists and support through the pre- to post-transplant journey.
“Following last year’s mention of AlloSure at the ATC 2020 State-of-the-Art Lecture by Alan Kirk, CareDx is building a track record of leading key developments in the field. In addition, Hannah highlights the importance of embracing diversity in the field of transplant medicine, a critical focus for us at CareDx as we see AlloSure data prove that the most vulnerable transplant patients come from underrepresented backgrounds,” said Sasha King, Chief Marketing Officer and Lead of the CareDx Diversity and Inclusion Committee.
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com
FAQ
What was the focus of Dr. Valantine's keynote at the ATC?
What is the AlloMap IMAGE trial?
How does CareDx address health disparities in transplantation?
What role does dd-cfDNA play according to Dr. Valantine?
